Biomedical Occupation or Discipline – Page 10

Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

5 months ago talkbio0Tagged Drug Development, Failure (biologic function), Kinevant, namilumab, Phase 2 clinical trial, Roivant, Sarcoidosis, Pulmonary

Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure

J&J’s Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal

5 months ago talkbio0Tagged Acquisition, Caplyta, Drug Industry, Duato, Intra-Cellular Therapies, Joaquin, Johnson and Johnson, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, acquisition, neuroscience, CAPLYTA, Joaquin Duato, pharmaceutical industry, M&A

Eli Lilly Streamlines Pipeline, Removing Alzheimer’s and Obesity Candidates in Q4 2024

5 months ago talkbio0Tagged Alzheimer 's disease, Ceperognastat, Clinical Trials, Drug Development, Eli, Eli Lilly, Obesity, pipeline update

Eli Lilly, pipeline update, Alzheimer’s disease, obesity, ceperognastat, clinical trials, drug development

Boston Scientific’s Farapulse PFA System Surpasses $1 Billion in Revenue, Transforming Electrophysiology Market

5 months ago talkbio0Tagged Atrial Fibrillation, Boston Scientific, Electrophysiology (science), Farapulse, field ablation, innovation, Medical Devices, Revenue Milestone

Boston Scientific, Farapulse, pulsed field ablation, atrial fibrillation, electrophysiology, revenue milestone, medical device innovation

Senator Cassidy’s Crucial Vote Advances RFK Jr.’s HHS Secretary Nomination

5 months ago talkbio0Tagged Administration occupational activities, Bill Cassidy, CHARGE Syndrome, HHS, public health medicine (field), Robert F. Kennedy, Secretary Nomination, Senate Finance Committee, Transplant Registry Unified Management Program, Vaccines

Robert F. Kennedy Jr., Bill Cassidy, HHS Secretary nomination, Senate Finance Committee, vaccine safety, public health, Trump administration

Omega Therapeutics Faces Bankruptcy and Layoffs Despite Recent Novo Nordisk Obesity Deal

5 months ago talkbio0Tagged Bankruptcy, deal, Epigenomics, financial struggles, Flagship, Nordisk, Obesity, Pioneering

Omega Therapeutics, bankruptcy, layoffs, Novo Nordisk, obesity deal, Flagship Pioneering, epigenomics, financial struggles

Thermo Fisher Scientific Continues Workforce Reduction with 300 Layoffs in Massachusetts

5 months ago talkbio0Tagged Biotechnology, cost-cutting measures, Industry, Massachusetts (geographic location), Thermo Fisher Scientific, Viral Vector

Thermo Fisher Scientific, layoffs, Massachusetts, viral vector production, workforce reduction, biotechnology industry, cost-cutting measures

Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension

5 months ago talkbio0Tagged Clinical Failure, Drug Development, IkT-001Pro, Inhibikase, Parkinson 's disease, Phase 2 Clinical Trials, Pulmonary arterial hypertension, risvodetinib

Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro

Sage Therapeutics Rejects Biogen’s Acquisition Proposal, Remains Open to Future Deals

5 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Neurodevelopmental Disorders, Neuropsychiatry, proposal - intent, Zurzuvae

Sage Therapeutics, Biogen, Acquisition Proposal, Postpartum Depression, ZURZUVAE, Neurodevelopmental Disorders, Neuropsychiatry

Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring

5 months ago talkbio0Tagged AK006, Allakos, Biotechnology, Chronic Spontaneous Urticaria, Failure (biologic function), Financial cost, phase 1 trial, restructuring, strategic alternatives

Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.